Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03612791
Title Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (ATEZOLACC)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Gustave Roussy, Cancer Campus, Grand Paris

cervical adenocarcinoma

cervical adenosquamous carcinoma

cervical squamous cell carcinoma



Atezolizumab + Cisplatin

Age Groups: adult | senior
Covered Countries FRA

No variant requirements are available.